Ertz-Archambault Natalie, Keim Paul, Von Hoff Daniel
Natalie Ertz-Archambault, Department of Internal Medicine, Mayo School of Graduate Medical Education, Mayo Clinic Arizona, Scottsdale, AZ 85259, United States.
World J Gastroenterol. 2017 Mar 14;23(10):1899-1908. doi: 10.3748/wjg.v23.i10.1899.
To review microbiome alterations associated with pancreatic cancer, its potential utility in diagnostics, risk assessment, and influence on disease outcomes.
A comprehensive literature review was conducted by all-inclusive topic review from PubMed, MEDLINE, and Web of Science. The last search was performed in October 2016.
Diverse microbiome alterations exist among several body sites including oral, gut, and pancreatic tissue, in patients with pancreatic cancer compared to healthy populations.
Pilot study successes in non-invasive screening strategies warrant further investigation for future translational application in early diagnostics and to learn modifiable risk factors relevant to disease prevention. Pre-clinical investigations exist in other tumor types that suggest microbiome manipulation provides opportunity to favorably transform cancer response to existing treatment protocols and improve survival.
综述与胰腺癌相关的微生物组改变、其在诊断、风险评估中的潜在用途以及对疾病结局的影响。
通过对PubMed、MEDLINE和Web of Science进行全面的主题检索，开展了一项综合性文献综述。最后一次检索于2016年10月进行。
与健康人群相比，胰腺癌患者的多个身体部位（包括口腔、肠道和胰腺组织）存在多种微生物组改变。
非侵入性筛查策略的初步研究成功，值得进一步研究以便未来在早期诊断中进行转化应用，并了解与疾病预防相关的可改变风险因素。其他肿瘤类型的临床前研究表明，微生物组调控为有利地改变癌症对现有治疗方案的反应及提高生存率提供了机会。
